Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT
02-Jan-2020 / 09:55 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Sartorius Stedim Biotech S.A. - 13781 Aubagne France
ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT
Aubagne, France | January 2, 2020
Under the liquidity contract concluded between Sartorius Stedim Biotech S.A. and the stockbroker Gilbert Dupont, the following assets appeared on the liquidity account at December 31, 2019:
Number of shares: 3,225 Liquidity account cash balance: € 370,692.66
For information, the following assets appeared on the half-year report of the liquidity contract of
June 28, 2019:
- Number of shares: 2,519
- Liquidity account cash balance: € 468,433.16
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2018, the company earned sales revenue of €1,212.2 million and currently employs more than 6,000 people.
Contact
Ben Orzelek
Investor Relations
+49(0)551.308.1668
Sartorius Stedim Biotech SA
Z.I. Les Paluds
Avenue de Jouques, CS 91051
13781 Aubagne Cedex, France
Phone: +33.(0)4.42.84.56.00
Fax: +33.(0)4.42.84.56.19
www.sartorius-stedim.com
Document title: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT
Document: http://n.eqs.com/c/fncls.ssp?u=OEYWCHJNRG
Language: English Company: Sartorius Stedim Biotech SA Avenue de Jouques 13781 Aubagne France Phone: +33 44 284 5600 E-mail: info@sartorius-stedim.com Internet: www.sartorius-stedim.com ISIN: FR0013154002 Euronext Ticker: DIM AMF Category: Share buyback / Disposal of own shares / Information relating to the liquidity contract EQS News ID: 945871 End of Announcement EQS News Service
945871 02-Jan-2020 CET/CEST